HDR radiation boost for prostate cancer during standard treatment
Part of Cancer, Kidney & urinary clinical trials.
This study tests adding a targeted “boost” of HDR (high-dose-rate) internal radiation to the prostate along with standard external beam radiation. It may help improve cancer control while keeping the treatment focused on the area seen on scans and biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by a tissue biopsy (or surgery pathology) and are planning curative radiation treatment
- Your radiation plan includes external beam radiation plus an HDR brachytherapy boost to the prostate
- Your general health is good to fair (ECOG 0–1, meaning you can do most daily activities)
- You have not too many other health problems (Charlson Comorbidity Index 4 or less)
- Scans show the tumor/area of concern in less than half of the prostate, and it matches your biopsy results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a targeted radiation boost to just the visible tumor versus boosting the whole prostate gland for men with localized prostate cancer. The goal is to see if a more focused approach works as well with fewer side effects.
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
This trial studies whether adding a stronger “boost” dose of targeted radiation (SBRT) can better control higher-risk prostate cancer. It may help by increasing radiation coverage to the prostate while trying to limit treatment to surrounding areas.
This trial tests a focused form of radiation placed inside the prostate to treat only the cancer area in people with low-risk prostate cancer. It aims to control the cancer while limiting treatment to a smaller area.
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
This trial tests a shorter course of radiation therapy (hypofractionated whole-pelvis radiation) combined with a high-dose-rate (HDR) brachytherapy boost for men with high-risk or unfavorable intermediate-risk prostate cancer. The goal is to see if this approach controls cancer while possibly reducing side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.